View Older Stories View More Recent Stories
-
Amicus Therapeutics and ARYA Sciences Acquisition Corp IV Announce Formation of a Next-Generation Genetic Medicine Company: “Caritas Therapeutics”
-
The New York Academy of Medicine to Honor Innovators in Health with Remarks from Dr. Anthony Fauci
-
Behavioral Health Leader Christina Mainelli Joins Quartet Health to Accelerate Strategic Growth
-
Vincerx Pharma, Inc (VINC) Announces 3.5M Share Private Placement at $14.50
-
Vincerx Pharma Announces $50 Million Private Placement
-
Dr. Patrice Harris Joins Quartet Health's Board of Directors
-
iECURE Launches With $50 Million Series A Financing to Develop In Vivo Gene Insertion Approaches for Devastating Diseases
-
HilleVax Closes $135 Million Crossover Financing to Advance Clinical Stage Norovirus Vaccine Candidate
-
Demy-Colton Announces BioFuture™ Speaker Lineup and Panel Sessions on October 5-6 at Cure by Deerfield in New York City
-
Form 4 Acutus Medical, Inc. For: Jun 17 Filed by: DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
-
Civetta Therapeutics Announces the Appointment of Christopher D. Roberts, Ph.D., as CEO
-
Lumos Pharma to Participate in September Investor Conferences
-
Lumos Pharma to Participate in September Investor Conferences
-
ARS Pharmaceuticals Raises $55 Million in Series D Funding for Launch Preparations of Neffy™ (epinephrine nasal spray)
-
The Cure Commences Fall Session of the Cure Symposia as Part of Its In-House Educational Programming
-
Blade Therapeutics Announces FDA Activation of IND Application to Investigate Cudetaxestat, a Non-Competitive Autotaxin Inhibitor, in Idiopathic Pulmonary Fibrosis (IPF)
-
Form 13F-HR DEERFIELD MANAGEMENT For: Jun 30
-
Form SC 13D DA32 Life Science Tech Filed by: DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
-
Form 4 DA32 Life Science Tech For: Aug 05 Filed by: DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
-
Miravo Healthcare™ Announces Second Quarter 2021 Results
-
Lumos Pharma Reports Second Quarter 2021 Financial Results and Provides Clinical and Corporate Updates
-
Lumos Pharma Reports Second Quarter 2021 Financial Results and Provides Clinical and Corporate Updates
-
PepGen Announces Closing of $112.5 Million Crossover Financing to Advance Transformative Therapies for Neuromuscular Diseases
-
Deerfield Announces New $1.4-billion Private Investment Fund
-
Form 4 DA32 Life Science Tech For: Jul 30 Filed by: DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
-
Lumos Pharma, Inc. (LUMO) Announces Industry Veteran, David B. Karpf, MD, has Joined the Company as Chief Medical Officer
-
Lumos Pharma Announces Industry Veteran, David B. Karpf, MD, has Joined the Company as Chief Medical Officer
-
Lumos Pharma Announces Industry Veteran, David B. Karpf, MD, has Joined the Company as Chief Medical Officer
-
Lumos Pharma, Inc. (LUMO) Announces the Promotion of COO and Chief Scientific Officer, John McKew, PhD, to President
-
Lumos Pharma Announces the Promotion of COO and Chief Scientific Officer, John McKew, PhD, to President
-
Lumos Pharma Announces the Promotion of COO and Chief Scientific Officer, John McKew, PhD, to President
-
Form 4 Nuvalent, Inc. For: Jul 28 Filed by: DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
-
DA32 Life Science Tech Acquisition Corp., Sponsored by Deerfield, ARCH Venture Partners and Section 32, Announces Closing of $200 Million Initial Public Offering
-
Strata Oncology Completes $90 Million Series C Financing
-
Bridge Medicines Enters Exclusive License Agreement with Cornell University for UBR5 Inhibitor Program to Treat Resistant Cancers
-
Form 3 DA32 Life Science Tech For: Jul 27 Filed by: DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
-
DA32 Life Science Tech Acquisition Corp., Sponsored by Deerfield, Arch Venture Partners and Section 32, Announces Pricing of $200 Million Initial Public Offering
-
Lumos Pharma Appoints Pediatric Endocrinologist Experienced in Clinical Research and Pharmaceutical Development, Mark Bach, M.D., Ph.D., to Clinical Scientific Advisory Board
-
Lumos Pharma Appoints Pediatric Endocrinologist Experienced in Clinical Research and Pharmaceutical Development, Mark Bach, M.D., Ph.D., to Clinical Scientific Advisory Board
-
Intersect ENT Announces Preliminary Revenue for Second Quarter of 2021 and Closing of $60 Million Term Loan
-
Lumos Pharma to Report Second Quarter 2021 Financial Results and Host Conference Call on August 5, 2021
-
Lumos Pharma to Report Second Quarter 2021 Financial Results and Host Conference Call on August 5, 2021
-
Axon Therapies Announces Chad Hoskins As Chief Executive Officer
-
Lumos Pharma (LUMO) issues new guidance concerning the Phase 2 OraGrowtH210 Trial of LUM-201 in PGHD
-
Lumos Pharma Announces Clinical Updates
-
Lumos Pharma Announces Clinical Updates
-
Humanity Health Launches to Address Lack of Diversity in Healthcare Leadership with Founding Investment from Deerfield Management
-
Frontier Medicines Raises $88.5 Million Series B Financing to Advance Precision Oncology and Targeted Protein Degradation Pipeline
-
Frontier Medicines Raises $88.5 Million Series B Financing to Advance Precision Oncology and Targeted Protein Degradation Pipeline
-
Endologix LLC Receives FDA Breakthrough Device Designation for ChEVAS™ System
